Evidence map›Paper›PMID 34003610›Full record

SynthesisInternational braz j urol : official journal of the Brazilian Society of Urology

Available evidence on HIFU for focal treatment of prostate cancer: a systematic review.

Arnas Bakavicius, Giancarlo Marra, Petr Macek, Cary Robertson, Andre L Abreu, Arvin K George, Bernard Malavaud, Patrick Coloby, Pascal Rischmann, Marco Moschini and 9 more

Registry-linked trialOpen access · diamondAbstract readSystematic Review
In one paragraph

Synthesis in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06929065 (Randomized Prospective Trial of Focal Therapy), which is not on this map. Cited by 38 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 4 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06929065 nacompletednot on this map

Randomized Prospective Trial of Focal Therapy (HIFU vs Cryo) for Early Stage Unifocal Prostate Cancer

TypeinterventionalSponsorKaiser PermanenteRan2023 to 2025Enrolled50ConditionsProstate Cancer, Prostate Cancer Stage I, Prostate Cancer Stage II, High Intensity Focused UltrasoundArmsHIFU vs Cryoablation
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Bibliometric analysis of high-intensity focused ultrasound.Frontiers in research metrics and analytics · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 7 countries.

Arnas BakaviciusFaculty of Medicine, Vilnius University, Vilnius, Lithuania.
Giancarlo MarraDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Petr MacekDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Cary RobertsonDepartment of Urology, Duke University, Durham, NC, USA.
Andre L AbreuDepartment of Urology, Keck School of Medicine and University of South California, CA, USA.
Arvin K GeorgeDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Bernard MalavaudDepartment of Urology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Patrick ColobyDepartment of Urology, Centre Hospitalier René-Dubos (Pontoise), France.
Pascal RischmannDepartment of Urology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
Marco MoschiniDepartment of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ardeshir R RastinehadDepartment of Urology, Lenox Hill Urology, NY, USA.
Abhinav SidanaDivision of Urology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Armando StabileDepartment of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Rafael Tourinho-BarbosaDepartamento de Urologia, Faculdade de Medicina do ABC (Faculdade de Medicina do ABC), São Paulo, Brasil.
Jean de la RosetteDepartment of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey.
Hashim AhmedFaculty of Medicine, Department of Surgery & Cancer, Imperial College London, United Kingdom.
Thomas PolascikDepartment of Urology, Duke University, Durham, NC, USA.
Xavier CathelineauDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Rafael Sanchez-SalasDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Institute Mutualiste Montsouris · FRDuke University · USInstitut universitaire du cancer de Toulouse Oncopole · FRVita-Salute San Raffaele University · ITCentre Hospitalier René-Dubos · FRFaculdade de Medicina do ABC · BRImperial College London · GBIstanbul Medipol University · TRKeck Hospital of USC · USLenox Hill Hospital · USUniversity of Cincinnati Medical Center · USUniversity of Michigan · USVilnius University · LT

Funding

Wellcome Trust 204998/Z/16/Z
6 · The paper itself

Abstract

purposeProstate cancer (PCa) is the second most common oncologic disease among men. Radical treatment with curative intent provides good oncological results for PCa survivors, although definitive therapy is associated with significant number of serious side-effects. In modern-era of medicine tissue-sparing techniques, such as focal HIFU, have been proposed for PCa patients in order to provide cancer control equivalent to the standard-of-care procedures while reducing morbidities and complications. The aim of this systematic review was to summarise the available evidence about focal HIFU therapy as a primary treatment for localized PCa. MATERIAL AND

methodsWe conducted a comprehensive literature review of focal HIFU therapy in the MEDLINE database (PROSPERO: CRD42021235581). Articles published in the English language between 2010 and 2020 with more than 50 patients were included.

resultsClinically significant in-field recurrence and out-of-field progression were detected to 22% and 29% PCa patients, respectively. Higher ISUP grade group, more positive cores at biopsy and bilateral disease were identified as the main risk factors for disease recurrence. The most common strategy for recurrence management was definitive therapy. Six months after focal HIFU therapy 98% of patients were totally continent and 80% of patients retained sufficient erections for sexual intercourse. The majority of complications presented in the early postoperative period and were classified as low-grade.

conclusionsThis review highlights that focal HIFU therapy appears to be a safe procedure, while short-term cancer control rate is encouraging. Though, second-line treatment or active surveillance seems to be necessary in a significant number of patients.

Indexed as

Prostatic NeoplasmsUltrasound, High-Intensity Focused, TransrectalHumansMaleNeoplasm Recurrence, LocalSalvage TherapyTreatment OutcomeHigh-Intensity Focused Ultrasound AblationProstate cancer, familial [Supplementary Concept]Technology; complications [Subheading]

Identifiers

PMID34003610
PMCPMC8932027
OpenAlexW3163881002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.